Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2709144 | 0.85 | TNKS (0.44) | POLBNPSR1KDM4EADORA2ALMNA | |
| SCHEMBL2859753 | 0.84 | NPSR1 (0.43) | POLBNPSR1KDM4EIGF1RADORA2A | |
| SCHEMBL7691626 | 0.81 | PARP1 (0.43) | POLBKDM4EADORA2AADORA1LMNA | |
| SCHEMBL1655812 | 0.78 | KCNH2 (0.49) | KDM4EADORA2AADORA1LMNAKCNH2 | |
| SCHEMBL2709776 | 0.78 | PRKD3 (0.40) | POLBKDM4EADORA2AADORA1LMNA | |
| SCHEMBL2709066 | 0.77 | ELANE (0.47) | KDM4EADORA2AADORA1LMNATRPA1 | |
| SCHEMBL2711485 | 0.77 | MAP4K4 (0.41) | POLBNPSR1KDM4EIGF1RADORA2A | |
| SCHEMBL31327745 | 0.77 | ENPP3 (0.48) | POLBKDM4EADORA2AADORA1LMNA | |
| SCHEMBL28858276 | 0.77 | ENPP3 (0.48) | POLBKDM4EADORA2AADORA1LMNA | |
| SCHEMBL19209596 | 0.76 | ACP1 (0.42) | POLBNPSR1IGF1REPHX2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106750314-B | Preparation method of organic silicon flame retardant for ABS resin | 普信氟硅新材料（衢州）有限公司 | 2020-02-18 | — | — | CN | claimed |
| US-20070148185-A1 | Novel therapeutic target for protozoal diseases | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY | 2007-06-28 | — | — | US | claimed |
| WO-2007047579-A2 | A NOVEL THERAPEUTIC TARGET FOR PROTOZOAL DISEASES | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| CN-106750314-B | Preparation method of organic silicon flame retardant for ABS resin | 普信氟硅新材料（衢州）有限公司 | 2020-02-18 | — | — | CN | disclosed |
| WO-2017136642-A1 | ANTIBIOTIC COMPOSITIONS | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017136642-A1 | ANTIBIOTIC COMPOSITIONS | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2017-08-10 | — | — | WO | disclosed |
| CN-106750314-A | A kind of preparation method of the organic silicon fibre retardant for ABS resin | 衢州普信新材料有限公司 | 2017-05-31 | — | — | CN | disclosed |
| EP-1505963-B9 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2340830-A2 | Hepatitis C Virus Inhibitors | Bristol-Myers Squibb Company (US) | 2011-07-06 | — | — | EP | disclosed |
| EP-1505963-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7790725-B2 | Thiazolidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-08 | — | — | US | disclosed |
| US-20040259883-A1 | Thiazolidine derivative and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1426366-A1 | THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | DPP4, DPP7, DPP3 | POLB 4577/4885NPSR1 1972/4885KDM4E 1080/4885 |
| US-20040259883-A1 | Thiazolidine derivative and medicinal use thereof | DPP4, DPP7, DPP3 | POLB 4576/4885NPSR1 1994/4885KDM4E 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.